CRISPR and Pfizer Stocks Offer Appeal for Different Types of Investors
-
CRISPR Therapeutics stock has advanced over 50% this year and has potential to climb further as its first approved product drives revenue growth.
-
Pfizer stock is very cheap right now with a forward P/E of just 9.8, and should return to growth once COVID product sales stabilize.
-
CRISPR's gene editing technology could lead to functional cures and has regulatory momentum, offering strong long-term potential.
-
Pfizer has multiple growth drivers beyond COVID products, including its RSV vaccine, migraine drug, rare heart drugs, and recent Seagen acquisition.
-
For income and value investors, Pfizer may be the better buy, while for growth investors, CRISPR likely has more appeal.